Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Biosciences Inc (APS.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 323,209
  • Shares Outstanding, K 55,487
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,868 K
  • 60-Month Beta 1.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.90
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings -0.12 on 09/30/19
  • Next Earnings Date 11/05/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +68.91%
on 11/15/19
5.98 -11.87%
on 12/12/19
+1.99 (+60.67%)
since 11/13/19
3-Month
2.37 +122.36%
on 10/23/19
5.98 -11.87%
on 12/12/19
+2.01 (+61.66%)
since 09/13/19
52-Week
2.08 +153.37%
on 03/05/19
5.98 -11.87%
on 12/12/19
+2.17 (+70.00%)
since 12/13/18

Most Recent Stories

More News
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019

Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat...

CNSP : 3.95 (-1.99%)
CLVS : 12.86 (-4.24%)
ARQL : 20.07 (+0.38%)
APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
FATE : 18.79 (-0.69%)
Aptose to Present at May Investor Conferences

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose Reports Results for the First Quarter Ended March 31, 2019

- Patient Dosed at Second Dose Level in APTO-253 Clinical Trial -

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting

-- Pan-FLT3/pan-BTK inhibitor CG-806 Demonstrates Significant and Superior Potency Against Primary Cells Across AML Types -

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Therapies Trying to Fight Against Cancer

Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
INO : 2.72 (+0.37%)
AGEN : 3.84 (+0.26%)
GILD : 65.77 (-2.75%)
CVM : 7.74 (+1.04%)
APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Therapies Trying to Fight Against Cancer

Over the past two decades, U.S. cancer-related deaths have significantly declined. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American Cancer...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
INO : 2.72 (+0.37%)
AGEN : 3.84 (+0.26%)
GILD : 65.77 (-2.75%)
CVM : 7.74 (+1.04%)
APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806

- CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML -

APTO : 4.07 (-8.45%)
APS.TO : 5.27 (-9.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar